Shrinking Tumors, Elevating Hope: FOLFIRINOX Impact on Pancreatic Cancer Resectability and Survival

In pancreatic cancer patients receiving FOLFIRINOX, tumor size reduction significantly increased resectability and pathologic response. Normalization of carbohydrate antigen 19-9 levels predicted resectability, lower recurrence risk, and improved survival. Postoperative antigen 19-9 rise, following prior normalization after neoadjuvant therapy, signaled heightened recurrence risk and poorer survival. Tailoring treatment response assessments can guide personalized strategies for pancreatic ductal adenocarcinoma management.